05 jan: DSV, 642 - Storaktionærmeddelelse
06 jan: Indre værdi af SmallCap Danmark A/S er opgjort til 84,4 kr. pr. ..
06-01-2017 07:58:46

Knud Vindfeldt steps down from the Executive Board of Chr. Hansen Holding A/S

Relateret indhold
19 okt - 
Chr. Hansen/Handelsbanken: Hæver kursmål til 600 kroner
11 okt - 
Onsdagens aktier: C20 sætter rekord efter revanche for ..
11 okt - 
Aktier/middag: Mærsk løfter C20 Cap i rekord - Matas i ..
Relateret debat
09 okt - 
og HVAD sker der så lige i dag ???
09 okt - 
Hvad sker der lige for Chr Hansen i dag ???????????
10 sep - 
Steget med en 50er siden regnskabet . Der komme snart e..

Hoersholm, 2017-01-06 07:58 CET (GLOBE NEWSWIRE) --

 

Company announcement No. 01/2017

After more than 25 years with Chr. Hansen and 11 years in Executive Management, Knud Vindfeldt will step down from the Executive Board of Chr. Hansen Holding A/S on 28 February 2017.

Knud Vindfeldt joined Chr. Hansen in 1991 and was appointed member of the Executive Board of Chr. Hansen Holding A/S and head of the Cultures & Enzymes Division in 2005, and was further appointed COO and Deputy CEO in 2016. After February, Knud will continue to support Chr. Hansen in the role of advisor to the CEO for a period of six months.

Cees de Jong, CEO of Chr. Hansen, says: “Knud has been one of the key drivers behind the success of Chr. Hansen in the dairy market, and he has relentlessly pushed for continued improvements in our strategic, operational and financial performance. The results delivered by the Food Cultures & Enzymes Division (FC&E) speak for themselves; since 2005, both revenue and EBIT margin have more than doubled.

“With the transfer of the commercial responsibility for FC&E to Christoffer Lorenzen in April last year, the recent recruitment of Thomas Schäfer as Chief Scientific Officer and, today, with the promotion of Torsten Steenholt to Executive Vice President, Global Operations and member of the Corporate Leadership Team, we have ensured Knud’s succession. On behalf of the entire Chr. Hansen organization, I would like to thank Knud for his exceptional contribution to Chr. Hansen and wish him all the best for the future.”

Knud Vindfeldt says: “Chr. Hansen is a truly great company and it has been a fantastic journey, which I am proud to have been part of. The company is in better shape than ever, delivering solid results. With such strong successors in place, I feel confident that this is a natural time for me to step down. In the coming months, we will ensure a good handover.”

Following this change, the Executive Board will consist of CEO Cees de Jong and CFO Søren Westh Lonning. In addition, and as previously announced, Thomas Schäfer will join Chr. Hansen as CSO and member of the Executive Board in due course.

For further information, please contact:

Anders Mohr Christensen, Senior Director, Investor Relations

Tel.: +45 4574 7618

Camilla Lercke, Head of Media Relations

Tel.: +45 5339 2384

 

About Chr. Hansen

Chr. Hansen is a global bioscience company that develops natural ingredient solutions for the food, nutritional, pharmaceutical and agricultural industries. The products include cultures, enzymes, probiotics and natural colors, and all solutions are based on strong research and development competencies coupled with significant technology investments. Revenue in the 2015/16 financial year was EUR 949 million. The company has more than 2,700 dedicated employees in 30 countries and main production facilities in Denmark, France, USA and Germany. Chr. Hansen was founded in 1874 and is listed on Nasdaq Copenhagen A/S. For further information, please visit www.chr-hansen.com.

 

Vedhæftet fil: No 01 2017 US.pdf

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Høreapparater: Sivantos-ledelse vil ikke sælge sminket lig

23-10-2017 15:32:25
I de seneste snart tre år har høreapparatproducenten Sivantos været under kapitalfonden EQT's vinger, efter at svenskerne overtog høreapparataktiviteterne fra kæmpekonglomeratet Siemens i november 2014.Dermed kan man måske så småt begynde at ænse et frasalg - eller en selvstændig børsnotering af selskabet - i horisonten, da kapitalfondernes formål typisk er at modne og effektivisere deres selskabe..

Novo: Analysehus ser høj encifret markedsvækst i USA - citat

23-10-2017 12:09:27
Det amerikanske marked for diabetesbehandling vil årligt vokse med høje encifrede vækstrater i det kommende årti, vurderer analysehuset Decision Resources ifølge Bloomberg Intelligence.Fremgangen vil være drevet af nye produkter, bredere funderede tilskud og stigende forekomst af diabetes, vurderer analysehuset.Markedet for apparatur til måling af blodsukkeret ventes at klare sig bedst og vil iføl..

Aktier/middag: Banker trækker ned i C20 løftet af FLS og DSV

23-10-2017 11:27:28
Med FLSmidth og DSV som trækheste ligger det danske C20 Cap-indeks mandag ved 11.15-tiden 0,3 pct. højere i 1186,20 og følger en lettere positiv tendens på hovedparten af de øvrige børser i Europa.Markedet kunne fra morgenstunden hente støtte i stigninger i Japan, hvor investorerne reagerede positivt på, at premierminister Shinzo Abe genvandt flertallet i parlamentet.Usikkerhed er der imidlertid f..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Aktier/tendens: Dobbeltløft til Novo inden blød start på aktieugen
2
Novo: Analysehus ser høj encifret markedsvækst i USA - citat
3
Novo/SHB: Kursmål sættes op til 403 kr. fra 357 kr. - NY
4
Aktier/Sydbank: Der skal opjusteringer til for at forlænge aktiefesten
5
Storbanks mistænkte valutasvindel fanget på bånd

Relaterede aktiekurser

Chr Hansen Holding A/S 541,00 0,0% Aktiekurs uændret

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2017  Disclaimer Privatlivspolitik
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
24. oktober 2017 04:12:48
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20171023.1 - EUROWEB5 - 2017-10-24 04:12:48 - 2017-10-24 04:12:48 - 1 - Website: OKAY